65,437 trials
Healthy Volunteers
Primary: AUC(0-tz) of Unconjugated Rotigotine — 4.3899; 4.4255 (ng/ mL)*h
Open-angle Glaucoma · Ocular Hypertension
Primary: Subject Reported Burning/Stinging — 1.1; 2.4 Units on a Scale — p=<.001
Human Immunodeficiency Virus - Type 1
Primary: Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR)…
Osteoarthritis of the Knee
Primary: Time-to-Exit From Current Study Treatment — 31; 20; NA; NA Days — p=0.1006
Dyslipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) (mg/dL) — -0.3; -1.5 Percent Change — p=0.926
Fever
Primary: The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2) — 0.3; 0.6 Degrees Celsius
Fever
Primary: Weighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of…
Osteoarthritis
Primary: The Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 6; 202 participants
Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 24 — -0.6 Percent — p=<0.001
Smoking · Nicotine Dependence
Primary: Weight Gain in Treatment Completers — 3.35; 4.14 Pounds
Overactive Bladder
Primary: The Global Response Assessment (GRA) for Overall Bladder Symptoms to Compare the Proportion of Subjects Reporting "Moderately" or "Markedly Improved" Responses on the…
Chronic Pain · Osteoarthritis of the Knee
Primary: "Average Pain Over the Last 24 Hours" Score of the Study Knee at Week 12 of the Double Blind Phase. — 7.16; 7.06; 2.63; 2.74 units on a scale — p=0.0853
Ulcerative Colitis
Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants
Myelodysplastic Syndromes
Primary: Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period — 39; 27; 20; 5 participants
Osteosarcoma
Primary: Percentage of Participants With Tumor Response — 3.1; 0; 3.1; 15.6 percentage of participants